midazolam has been researched along with quercetin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Furukawa, T; Hosoya, K; Kadono, K; Moriguchi, H; Nakamori, F; Naritomi, Y; Teramura, T; Terashita, S; Tetsuka, K; Yamano, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Bansod, KU; Dixit, PV; Kumar, V; Umathe, SN; Wanjari, MM | 1 |
| Duan, KM; Mao, YM; Ouyang, W; Wang, SY; Yang, LJ | 1 |
| Langguth, P; Nguyen, MA; Staubach, P; Wolffram, S | 1 |
| Birangal, S; Kadari, S; Patil, PH; Pinjari, J; Puralae Channabasavaiah, J; Rao, M; Rastogi, H; Sharma, T; Shenoy, GG; Wankhede, A | 1 |
2 trial(s) available for midazolam and quercetin
| Article | Year |
|---|---|
Effect of quercetin on CYP3A activity in Chinese healthy participants.
Topics: Adult; Alleles; China; Cross-Over Studies; Cytochrome P-450 CYP3A; Dietary Supplements; Enzyme Induction; Food-Drug Interactions; Gene Frequency; Genetic Association Studies; Half-Life; Humans; Male; Metabolic Detoxication, Phase I; Midazolam; Polymorphism, Single Nucleotide; Quercetin; Young Adult | 2012 |
The Influence of Single-Dose and Short-Term Administration of Quercetin on the Pharmacokinetics of Midazolam in Humans.
Topics: Administration, Intravenous; Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Male; Midazolam; Quercetin | 2015 |
8 other study(ies) available for midazolam and quercetin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Topics: Administration, Oral; Biotransformation; Cell Membrane Permeability; Cytochrome P-450 Enzyme System; Glucuronides; Glucuronosyltransferase; Humans; Intestinal Absorption; Intestines; Isoenzymes; Kinetics; Metabolic Clearance Rate; Microsomes; Models, Biological; Pharmaceutical Preparations; Recombinant Proteins; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition.
Topics: Animals; Antioxidants; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Female; Hypoglycemic Agents; Microsomes; Midazolam; Pioglitazone; Quercetin; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2008 |
Molecular dynamics simulation and in vitro evaluation of herb-drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy.
Topics: Breast Neoplasms; Curcumin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Herb-Drug Interactions; Humans; Microsomes, Liver; Midazolam; Molecular Dynamics Simulation; Polyphenols; Quercetin | 2022 |